enGene Therapeutics Inc. (ENGN)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.73 on 9 Oct 2026

1 buy0 sales at will0 planned sales

Fiscal year 2025, ended 31 Oct 2025, as filed

Net income

$117.30M

Free cash flow

$100.72M

Return on equity

-69.9%

Return on capital

-58.0%

EPS growth, 1 yr

56.9%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
22 Sep 2026	Grossman William Interim Chief Medical Officer	Bought	$10.05K	opened
30 Oct 2024	Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Bought	$5.00M	22.7%
8 Oct 2024	Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Bought	$5.28K	0.0%
7 Oct 2024	Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Bought	$77.53K	0.5%
4 Oct 2024	Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Bought	$39.24K	0.2%
3 Oct 2024	Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner	Bought	$37.40K	0.2%

29out of 100

Profitability 0

Financial strength 60

Growth 0

Insiders 70

Strongest on insiders (70), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$10.05K

1 buy, 1 buyer

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan